Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Fig. 1

Serological responses to vaccination. Titers from cancer patients undergoing PD-1 blockade (Pat) and healthy age-matched controls (HD) against Influenza A/H1N1 (a), Influenza A/H3N2 (b), and Influenza B/Brisbane (c) after different time points after vaccination. The titers were determined by hemagglutination inhibition assay. The seroconversion factor indicates the ration between post- and pre-vaccine titers for all three antigens at day 30 (d). Mann-Whitney U test was used with a significance level of 0.05, two-sided

Back to article page